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Background
Apoptosis is believed to play a major role in the progres-
sive weakening of the peri-infarct and remote zone myo-
cardium after myocardial infarction (MI). Our laboratory
previously developed an in vivo, MRI-detectable apoptosis
probe. Annexin-V (ANX), which binds to cells undergoing
apoptosis, was conjugated to superparamagnetic iron
oxide (SPIO) nanoparticles, allowing for the non-invasive
detection of early apoptotic cell populations (ANX-SPIO
r1: 8.6 ± 0.61 mM-1 s-1 and r2: 326 ± 16 mM-1 s-1).
In recent work, we demonstrated A61603 (A6), an a1-
adrenergic receptor agonist, can rescue cardiac cells from
apoptosis through activation of the cardio-protective ERK
pathway. We tested whether pre-treatment with A6 was
able to prevent the functional decline after MI via an anti-
apoptotic mechanism, and whether T2* cardiac MRI,
using ANX-SPIO, was sensitive to this dynamic protective
effect. Our hypothesis was that A6 pre-treatment protects
against MI-induced cardiomyopathy more effectively than
A6 treatment after MI.
Methods
Female fvb/n mice were divided into three experimental
groups. The A6 PREMI group underwent subcutaneous
pump implant that delivered A6 two days before LAD liga-
tion. The A6 MI and vehicle (VEH) groups underwent MI
surgery simultaneously with subcutaneous A6 or vehicle
pump implantation. Pump rate was 10 ng/kg/day over a
course of two weeks, and all groups had their pumps re-
implanted after two weeks. Cardiac MRI (CMR) was per-
formed at 1, 2, and 4 weeks post MI. ANX-SPIO was deliv-
ered via tail vein one day prior to CMR to simultaneously
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Figure 1 A) Cardiac ejection fraction (EF) at early (1-2 weeks) and
late (4 week) timepoints post-MI. A6 PREMI exhibits significantly
greater preservation of EF compared to A6-MI and VEH treated mice
at an early timepoint. At late followup (4 weeks), only A6 PREMI
animals exhibited significantly higher EF than VEH-treated controls,
indicating the importance of pre-treatment with A6. B) Caspase
activity blunted by A6 treatment. Caspase activity measured in
hearts after two weeks of continuous treatment with either A6
(10ng/kg/d) or VEH solution. Note the significantly reduced caspase
activity in A6-MI hearts compared to positive control (PC,
Doxorubicin-treated hearts), whereas VEH-MI hearts were not
significantly different from PC hearts. In addition, negative control
hearts had significantly lower caspase activity levels than VEH-MI
hearts, but not A6-MI hearts.
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assess left ventricular function and apoptosis (using T2* sig-
nal loss as a marker of apoptotic activity) in vivo. Delayed
gadolinium enhancement MRI (DEMRI) and T2* were
assessed by GE 3T Signa Excite HD MRI: GRE TR 100ms,
TE 5-20ms, FA60, 256x256, FOV 4, ST 0.8mm, NEX 6.
Myocardial caspase 3/7 activities were also assessed in each
group.
Results
At 1-2 weeks post-MI, A6 PREMI EFs (48±10%, n=4)
were significantly higher than A6 MI EFs (36±10%,
n=10), and both were significantly higher than VEH (16
±6%, n=13) mice (p<0.001). At 4 weeks, however, only
A6PREMI mice (35±6%) exhibited sustained cardiac
function, with a significantly higher ejection fraction
than VEH mice (19±6) at week 4 (p<0.01) (Figure 1A).
The preserved EF in the A6-MI mice was associated
with significantly lower myocardial Caspase 3/7 activity
(Figure 1B). Upon T2* decay assessment, A6-treated
mice showed significantly (p<0.05) less T2* signal loss
after ANX-SPIO delivery compared to VEH-treated
mice at 1 week post MI (A6 T2*: 19±2ms; VEH T2*: 14
±1, n=3), reflecting less myocardial uptake of ANX-
SPIO and therefore less cardiac cell apoptosis in A6-
treated hearts (Figure 2).
Conclusions
A6 pretreatment attenuates the decline in cardiac func-
tion post-MI, compared to A6 post-treatment. T2* Car-
diac MRI using ANX-SPIO is able to detect the anti-
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Figure 2 a) CMR images of short-axis VEH-MI heart showing T2*
signal loss from ANX-SPIO update in the remote and border zones
(arrows). b) CMR images of A6-MI heart showing visibly ANX-SPIO
T2* signal loss. c) T2* decay curves showing more rapid T2* decay
in VEH-MI hearts compared to A6-MI hearts.
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